Evidence map›Paper›PMID 30504332›Full record

ReviewHematology. American Society of Hematology. Education Program2018

Potential new approaches to the management of the Hb Bart's hydrops fetalis syndrome: the most severe form of α-thalassemia.

Andrew J King, Douglas R Higgs

Open access · bronzeAbstract readReview
In one paragraph

Review in Hematology. American Society of Hematology. Education Program, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Molecular Basis and Genetic Modifiers of Thalassemia.Hematology/oncology clinics of North America · 2023
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Advances in the management of α-thalassemia major: reasons to be optimistic.Hematology. American Society of Hematology. Education Program · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Andrew J KingWeatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom.
Douglas R HiggsWeatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom.
John Radcliffe Hospital · GB

Funding

Medical Research Council 4050189188Medical Research Council G1000801Medical Research Council MC_PC_15069Medical Research Council MC_U137961144Medical Research Council MC_U137961145Medical Research Council MC_UU_00016/4Medical Research Council MC_UU_12009/4Wellcome TrustWellcome Trust 108785/Z/15/Z
6 · The paper itself

Abstract

The α-thalassemia trait, associated with deletions removing both α-globin genes from 1 chromosome (genotype ζ αα/ζ--), is common throughout Southeast Asia. Consequently, many pregnancies in couples of Southeast Asian origin carry a 1 in 4 risk of producing a fetus inheriting no functional α-globin genes (ζ--/ζ--), leading to hemoglobin (Hb) Bart's hydrops fetalis syndrome (BHFS). Expression of the embryonic α-globin genes (ζ-globin) is normally limited to the early stages of primitive erythropoiesis, and so when the ζ-globin genes are silenced, at ∼6 weeks of gestation, there should be no α-like globin chains to pair with the fetal γ-globin chains of Hb, which consequently form nonfunctional tetramers (γ

Indexed as

alpha-ThalassemiaBlood Transfusion, IntrauterineHemoglobins, AbnormalHydrops FetalisHumansPerinatal Carehemoglobin Bart'sHemoglobins, Abnormal

Identifiers

PMID30504332
PMCPMC6246003
OpenAlexW2903168130

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.